Evidence map›Paper›PMID 40878326›Full record

ArticleThe Indian journal of medical research2025

QT interval prolongation in schizophrenia: A cross-sectional study from a tertiary care center in Raipur.

Mishthi Malani, Shrayasi Das, Anirban Saha, Ajay Kumar, Satyajit Singh, Aditya Somani

Abstract read
In one paragraph

Article in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Authors' response.The Indian journal of medical research · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mishthi MalaniDepartment of Cardiology, †All India Institute of Medical Sciences Raipur, Chhattisgarh, India.
Shrayasi DasDepartment of Psychiatry, All India Institute of Medical Sciences Raipur, Chhattisgarh, India.
Anirban SahaDepartment of Psychiatry, All India Institute of Medical Sciences Raipur, Chhattisgarh, India.
Ajay KumarDepartment of Psychiatry, All India Institute of Medical Sciences Raipur, Chhattisgarh, India.
Satyajit SinghDepartment of Cardiology, †All India Institute of Medical Sciences Raipur, Chhattisgarh, India.
Aditya SomaniDepartment of Psychiatry, All India Institute of Medical Sciences Raipur, Chhattisgarh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & objectives Antipsychotic drugs can cause QT interval prolongation (QTIP), which can lead to life-threatening cardiac manifestations. The objective of this study was to find out the prevalence of QTIP in stable patients of schizophrenia attending the outpatient department/clinic. Methods A total of 88 consenting individuals with schizophrenia aged ≥18 yr of either sex (male or female), who were stable on treatment and adherent to the prescribed medications, were included. Patients with any other psychiatric disorder, mental retardation, substance dependence other than caffeine/nicotine, or if they had taken any other drug with moderate to high risk of causing QTIP, were excluded. A 12-lead ECG was recorded. Corrected QT interval was calculated using Fridericia's and Bazett's formulae. Results QTIP was seen in 3 (3.4%) study participants according to Fridericia's formula and in 6 (6.8%) study participants according to Bazett's formula. The recorded demographic, anthropometric, and clinical/treatment variables did not differ among participants with and without QTIP. Interpretation & conclusions Prevalence of antipsychotic drug-induced QTIP in patients with schizophrenia seems to be low, but it poses a risk to life. Regular screening for additional risk factors and periodic assessment of cardiac rhythm via ECG could help prevent potentially fatal cardiac manifestations.

Indexed as

Antipsychotic AgentsLong QT SyndromeSchizophreniaAdultCross-Sectional StudiesElectrocardiographyFemaleHumansMaleMiddle AgedPrevalenceRisk FactorsTertiary Care CentersAntipsychotic AgentsAntipsychotic drugsECGpatient safetyQT interval prolongationSchizophreniaTorsades de Pointes

Identifiers

PMID40878326
PMCPMC12550426

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.